Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | BCL9 | O00512 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15459741 | 0.88 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL2233659 | 0.87 | HTR2A (0.52) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL2236491 | 0.86 | HTR2A (0.52) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL7989561 | 0.85 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL2232343 | 0.84 | HTR2A (0.48) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL1036489 | 0.84 | HTR2A (0.52) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL23203128 | 0.83 | HTR2A (0.49) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL2235137 | 0.83 | BCL9 (0.56) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL8605685 | 0.83 | HTR2A (0.49) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL23202970 | 0.83 | HTR2A (0.49) | HTR2AGAABCL9CTNNB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160665-A1 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-24 | — | — | US | claimed |
| WO-2010063002-A2 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-03 | — | — | WO | claimed |
| US-20260138964-A1 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | TRANSCEND THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-12473295-B2 | Substituted straight chain spiro derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| EP-4635958-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-10-22 | — | — | EP | disclosed |
| US-20250270242-A1 | PHENETHYLAMINES AND CATHINONES PRECURSORS | TRANSCEND THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4605385-A1 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | Transcend Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4573084-A1 | PHENETHYLAMINES AND CATHINONES PRECURSORS | Transcend Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250197398-A1 | Varenicline Related Compounds and Methods for Treating Diseases and Conditions Including Tobacco Use Disorder | SPACERX LLC | 2025-06-19 | — | — | US | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20100160665-A1 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-24 | — | — | US | disclosed |
| US-20100160665-A1 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-24 | — | — | US | disclosed |
| US-20100160665-A1 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-24 | — | — | US | disclosed |
| WO-2010063002-A2 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010063002-A2 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-03 | — | — | WO | disclosed |
| US-5789595-A | ANTICOAGULANTS | TERUMO KABUSHIKI KAISHA (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0790247-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND MEDICINAL PREPARATION CONTAINING THE SAME | TERUMO KABUSHIKI KAISHA (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270242-A1 | PHENETHYLAMINES AND CATHINONES PRECURSORS | PNMT, COMT, SLC18A1 | HTR2A 19/4885GAA 816/4885BCL9 1460/4885 |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | HTR2A 4341/4885GAA 1535/4885BCL9 2611/4885 |
| US-20100160665-A1 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL | ADH1C, CNR1, GABRG1 | HTR2A 3951/4885GAA 3240/4885BCL9 2017/4885 |
| US-12473295-B2 | Substituted straight chain spiro derivatives | MLLT1, MEN1, MLLT3 | HTR2A 4666/4885GAA 4450/4885BCL9 40/4885 |
| US-20260138964-A1 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | DMPK, CHKB, TTK | HTR2A 948/4885GAA 2742/4885BCL9 1377/4885 |
| US-20250197398-A1 | Varenicline Related Compounds and Methods for Treating Diseases and Conditions Including Tobacco Use Disorder | COMT, CACNA1S, SMOX | HTR2A 272/4885GAA 386/4885BCL9 2415/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | HTR2A 3849/4885GAA 2063/4885BCL9 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.